Resources

Just one month after launch, five early-stage science companies have moved into the Leap incubator lab space at ARC West London. The first cohort of innovators joining Leap includes: Solveteq, Reseda Life Sciences, Tachmed, IgEDAPT, and Sea2Carbon.

eXmoor Pharma, the integrated cell and gene therapy CDMO with embedded consultancy expertise, and Royal Free London NHS Foundation Trust, through its Cell and Vector Innovation Centre (CVIC), have entered a strategic collaboration to build a seamless, scalable pathway for cell and gene therapy development and manufacturing in the UK.

Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.

In this spotlight feature, Bev Cameron, Sales Director for EMEA & APAC at Aldevron, shares how the company is helping accelerate next-generation genomic medicines, from personalised CRISPR therapies to ready-to-scale platforms that support innovators across the development journey.

The UK’s used nuclear materials will be recycled to create an evergreen supply of new precision cancer medicines, offering hope for patients with previously untreatable cancers.

LinkGevity's first-in-class Anti-Necrotic drug was featured in the Sunday Express this week. The article highlights the transformative potential of targeting necrosis- a long-overlooked driver of age-related degeneration.

In its latest annual review, the CGT Catapult demonstrates how it is uniquely positioned to deliver critical advances in the cell and gene therapy industry, from driving forward the industry’s productivity for the economy to improving patient outcomes.

A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.

VectorBuilder, a global leader in gene delivery technologies and CDMO services, today announced the publication of the miniVec plasmid system, engineered for safer, more efficient, and more scalable development of genetic medicines. The manuscript detailing this breakthrough is now available on BioRxiv.

How are pharmaceutical companies, policymakers and investors seeking growth amid fast-changing international politics, trade deals, a looming patent cliff, and technological innovation? Our maiden Life sciences and healthcare insights report offers a global perspective on disruptive forces from artificial intelligence to regulatory shifts.

Complement Therapeutics receives FDA IND clearance to advance its lead gene therapy CTx001 into Opti-GAIN, a Phase I/II clinical trial in Geographic Atrophy secondary to AMD

Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing.

VectorBuilder wins two IMAPAC awards, cementing leadership in gene therapy and CDMO innovation

The Life Sciences Learner Hub – the evolution of the proven ATSTN Online Training Platform, now expanded to serve the broader life sciences community.

Darren Blamire, Autolus, and Diana Hernandez, Anthony Nolan, will steer BIA’s Cell and Gene Therapy Advisory Committee, driving UK leadership and patient access in this transformative field.

Poolbeg Pharma plc, headquartered in London and listed on AIM, is running a UK-based clinical trial of POLB 001 to test its ability to prevent cancer immunotherapy-induced cytokine release syndrome (CRS)—a major bottleneck to the wider rollout of breakthrough cancer immunotherapies.

In this blog, Alan Griffith, Head of CDMO Global Operations, shares their achievements, priorities, and ambitions as a new member of the BIA community.

Cell and Gene Therapy Catapult (CGT Catapult), is working with VascVersa to develop a test that predicts the clinical efficacy of its experimental cell therapy for ischaemic diseases. This test will be used as a qualified assay as part of the cell manufacturing process.

The global collaboration provides an integrated translational biology platform to accelerate the development of novel radiopharmaceuticals.